Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-454047·Aspen Neuroscience, Inc.
Schedule 13D ownership disclosure
Aspen Neuroscience, Inc.
Common stock, par value $0.0001 per share · CUSIP: 044933109
Event date: 2026-11-02
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ARCH Venture Fund X, L.P.Reported CIK 0001757011
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Partners X, L.P.Reported CIK 0001782583
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Fund X Overage, L.P.Reported CIK 0001757017
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Partners X Overage, L.P.Reported CIK 0001768905
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Partners X, LLCReported CIK 0001769012
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Fund XIV, L.P.Reported CIK 0002138046
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Partners XIV, L.P.Reported CIK 0002147717
Shares: 3,754,922 · Class: 12.9%
- ARCH Venture Partners XIV, LLCReported CIK 0002148927
Shares: 3,754,922 · Class: 12.9%
- Robert NelsenReported CIK 0001219042
Shares: 3,754,922 · Class: 12.9%
- Keith CrandellReported CIK 0001219039
Shares: 3,754,922 · Class: 12.9%
- Kristina BurowReported CIK 0001569248
Shares: 3,754,922 · Class: 12.9%
- Steven GillisReported CIK 0001229592
Shares: 3,754,922 · Class: 12.9%
- Paul BernsReported CIK 0001202769
Shares: 1,200,000 · Class: 4.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-454047
- Form type
- SCHEDULE 13D
- Filer
- Aspen Neuroscience, Inc.
- CIK
- CIK 2124080
- Filed
- Nov 09, 2026
- Reporting period
- Nov 02, 2026
- Description
- Schedule 13D beneficial ownership